Ceralasertib Plus Olaparib for Homologous Recombination–Deficient Ovarian Cancer With Acquired PARP Inhibitor Resistance
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer
Clin. Cancer Res 2023 Aug 01;29(15)2800-2807, SL Wethington, PD Shah, L Martin, JL Tanyi, N Latif, M Morgan, DA Torigian, D Rodriguez, SA Smith, E Dean, SM Domchek, R Drapkin, IM Shih, EJ Brown, WT Hwang, DK Armstrong, S Gaillard, R Giuntoli, F SimpkinsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.